Company / Working Capital
Q32 Bio Inc. Working Capital History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$43.7M
FY2025
5-year range
$43.7M / $174.7M
FY2021-FY2025
Trend
-33.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has declined for 6 consecutive years, from $254M in FY2019 to $44M in FY2025.
Based on SEC 10-K filings.
$44M in FY2025 with a 5-year CAGR of -26.0%.
Declined from $72M to $44M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -34.9%
- 5-Year CAGR
- -26.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- Q32 Bio Inc.'s working capital has declined for 6 consecutive years.
- 5-year CAGR of -26.0%, indicating a declining trend.
- In FY2025, working capital decreased 33.2% year-over-year.
- Peak working capital was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $43.7M | -33.2% |
| FY2024 | $65.4M | -9.6% |
| FY2023 | $72.3M | -54.3% |
| FY2022 | $158.4M | -9.3% |
| FY2021 | $174.7M | -11.3% |
| FY2020 | $196.9M | -22.5% |
| FY2019 | $254.2M | +29.5% |
| FY2018 | $196.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026